CELLTRION HEALTHCARE CO., LTD. Inactive Instrument
Funds and ETFs Celltrion Healthcare Co., Ltd.
Equities
A091990
KR7091990002
Pharmaceuticals
ETFs positioned on Celltrion Healthcare Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.95% | 2 M€ | -14.14% | ||
| 0.22% | 15 M€ | +11.24% | ||
| 0.09% | 1 M€ | +3.49% | - | |
| 0.09% | 3 M€ | -.--% | - | |
| 0.08% | 441 M€ | +4.60% | - | |
| 0.08% | 2,808 M€ | +5.90% | - | |
| 0.08% | 149 M€ | +2.17% | - | |
| 0.07% | 4 M€ | -4.41% | - | |
| 0.02% | 7 M€ | +1.95% | - | |
| 0.02% | 117 M€ | +1.11% | - | |
| 0.01% | 34 M€ | +6.71% | - | |
| 0.00% | 302 M€ | +3.80% | - | |
| 0.00% | 39 M€ | +3.67% | - | |
| 0.00% | 389 M€ | +6.83% | - | |
| 0.00% | 147 M€ | +4.88% | - | |
| 0.00% | 108 M€ | +2.03% | - | |
| 0.00% | 17 M€ | +1.44% | - | |
| 0.00% | 7 M€ | +0.11% | - | |
| 0.00% | 34 M€ | +2.14% | - | |
| 0.00% | 52 M€ | -0.60% | - | |
| 0.00% | 8 M€ | -0.60% | - |
Celltrion Healthcare Co Ltd is a Korea-based company principally engaged in the marketing and distribution of biopharmaceuticals. The Company provides Remsima, an infliximab biosimilar used for the treatment of rheumatoid arthritis, ankylosing spondylitis, adult and child crohn's disease, psoriasis, psoriatic arthritis and ulcerative colitis. It also offers Truxima, a rituximab biosimilar used for the treatment of non-Hodgkin lymphomas, chronic lymphocytic leukemia and rheumatoid arthritis. The Company distributes its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
